&w=3840&q=100)
Lilly's obesity drug Mounjaro's sales rise 60% in India amid rising demand
Eli Lilly & Co. increased sales of weight-loss and diabetes drug Mounjaro 60 per cent in India in May from April in its second full month of being on offer in the South Asian country, which has the world's third-highest number of obese people.
The US drugmaker sold ₹12.6 crore ($1.5 million) worth of the injections last month, according to market analysis firm Pharmarack Technologies. Sales of its 5 mg version more than doubled to about ₹7.5 crore, while revenue from the 2.5 mg shot was ₹5.1 crore.
'The patient number may have actually doubled' in May from April, Pharmarack Vice President Sheetal Sapale told Bloomberg News. The demand is gradually rising and should continue, she said. Newer patients are being introduced with the lower dose and upgraded to 5 mg injections after four weeks, according to Sapale.
The increase in sales reflects the need for anti-obesity solutions in the vast market in India, where Danish rival Novo Nordisk A/S is also expected to launch soon. The country's generic drugmakers are awaiting the expiration of some patents from next year to unleash a flurry of copycat treatments.
On Tuesday, Biocon Ltd. received approval for Liraglutide, a generic version of Novo Nordisk's type-2 diabetes and anti-obesity drug Victoza.
India has about 100 million people living with diabetes and obesity each, Eli Lilly said earlier this year.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
5 hours ago
- Time of India
Weight-loss drug bulks up sales as patients upgrade dosage
Eli Lilly's weight-loss and diabetes drug, Mounjaro, has rapidly gained popularity in India, achieving Rs 24 crore in sales within three months. Young adults in their 30s and 40s are showing significant interest, with many upgrading to higher doses. While experts acknowledge its potential in addressing obesity, they caution about long-term efficacy, side effects, and affordability for the Indian population. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Mumbai: Sales of Mounjaro, Eli Lilly 's blockbuster weight-loss and diabetes drug, have touched Rs 24 crore within three months of its India launch, making it one of the most popular and fastest adopted new drugs in the country, with many people in their thirties and early forties showing sales grew 60% month on month to Rs 12.60 crore last month from Rs 7.87 crore in April, with the 5 mg injections accounting for Rs 7.53 crore—up 145% from Rs 3.08 crore in the previous month, data from industry tracker PharmaTrac showed. This indicates that patients are upgrading to higher doses after taking an initial base dose of 2.5 mg, experts doctors recommend a dose escalation to 5 mg after one month of starting the medication, depending on side effects. Mounjaro is currently available in 2.5 mg and 5 mg injections in India. Sales of 2.5 mg injections rose to Rs 5.08 crore in May from Rs 4.80 crore in April and Rs 1.42 crore in March, when it was launched, according to PharmaTrac data.'Our data indicates patients upgrading to higher dose after four weeks as well as new patients onboarding on lower dose,' said Sheetal Sapale, vice president, commercial, at endocrinologists said many people in their 30s and early 40s are reaching out to doctors to check if they could use the medication to lose weight.'There are many young people asking me if they could use the drug,' said Vyankatesh Shivane, diabetology and endocrinology consultant at Jaslok Hospital & Research Centre in Mumbai. He said Indian patients are responding well to tirzepatide (Mounjaro).'Clinical trials conducted previously on Indian obese diabetes patients have shown good weight loss benefits at more than 20% as well as good sugar control,' Shivane said. 'Both semaglutide (Novo Nordisk's Wegovy) and tirzepatide have completed cardiovascular safety trials and have shown added benefits of reduction of cardiovascular events in Type 2 diabetes patients,' he drugmaker Novo Nordisk is expected to launch its blockbuster weight-loss drug Wegovy in India this year. Doctors said medications like Mounjaro and Wegovy could prove an actionable remedy in a country of 80 million obese they cautioned that it would take four to six months to assess their effect on a larger Indian population regarding actual weight loss efficacy, potential weight regain after stopping the medication, and side to Shivane, clinical trails have shown weight regain of 5-7% once the drug is stopped. 'That is where patients will need counselling in order to adopt a healthier lifestyle including healthy dietary habits and regular exercise,' he Kumar Sinha, consultant physician at Mumbai-based WeCare Wellness, said, 'The molecule is good. Global studies suggest there are patients who have benefitted from it, but there are also those who have dropped out due to side effects that are mostly gastrointestinal in nature.' Commonly reported side effects include nausea, vomiting, diarrhoea, constipation and abdominal pain. Sinha said it will take 3-4 months to tell how the drug is working on Indian patients. 'One also has to look at the affordability issue,' he added. In India, Mounjaro is priced at Rs 3,500 for a 2.5 mg vial and Rs 4,375 for a 5 mg vial, which translates to Rs 14,000-17,500 per month, depending on the weekly dose. This means a six month treatment could cost about Rs 1 to a recent study published in leading medical journal Lancet, 70% of India's urban population is classified as obese, or overweight.'Obesity is like a pandemic in India and diabetes is very common and it is one of the useful drugs,' Anurag Lila, visiting consultant endocrinologist at Dr LH Hiranandani Hospital in Mumbai, told ET in a recent interaction.
Economic Times
5 hours ago
- Economic Times
Weight-loss drug bulks up sales as patients upgrade dosage
Eli Lilly's weight-loss and diabetes drug, Mounjaro, has rapidly gained popularity in India, achieving Rs 24 crore in sales within three months. Young adults in their 30s and 40s are showing significant interest, with many upgrading to higher doses. While experts acknowledge its potential in addressing obesity, they caution about long-term efficacy, side effects, and affordability for the Indian population. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Mumbai: Sales of Mounjaro, Eli Lilly 's blockbuster weight-loss and diabetes drug, have touched Rs 24 crore within three months of its India launch, making it one of the most popular and fastest adopted new drugs in the country, with many people in their thirties and early forties showing sales grew 60% month on month to Rs 12.60 crore last month from Rs 7.87 crore in April, with the 5 mg injections accounting for Rs 7.53 crore—up 145% from Rs 3.08 crore in the previous month, data from industry tracker PharmaTrac showed. This indicates that patients are upgrading to higher doses after taking an initial base dose of 2.5 mg, experts doctors recommend a dose escalation to 5 mg after one month of starting the medication, depending on side effects. Mounjaro is currently available in 2.5 mg and 5 mg injections in India. Sales of 2.5 mg injections rose to Rs 5.08 crore in May from Rs 4.80 crore in April and Rs 1.42 crore in March, when it was launched, according to PharmaTrac data.'Our data indicates patients upgrading to higher dose after four weeks as well as new patients onboarding on lower dose,' said Sheetal Sapale, vice president, commercial, at endocrinologists said many people in their 30s and early 40s are reaching out to doctors to check if they could use the medication to lose weight.'There are many young people asking me if they could use the drug,' said Vyankatesh Shivane, diabetology and endocrinology consultant at Jaslok Hospital & Research Centre in Mumbai. He said Indian patients are responding well to tirzepatide (Mounjaro).'Clinical trials conducted previously on Indian obese diabetes patients have shown good weight loss benefits at more than 20% as well as good sugar control,' Shivane said. 'Both semaglutide (Novo Nordisk's Wegovy) and tirzepatide have completed cardiovascular safety trials and have shown added benefits of reduction of cardiovascular events in Type 2 diabetes patients,' he drugmaker Novo Nordisk is expected to launch its blockbuster weight-loss drug Wegovy in India this year. Doctors said medications like Mounjaro and Wegovy could prove an actionable remedy in a country of 80 million obese they cautioned that it would take four to six months to assess their effect on a larger Indian population regarding actual weight loss efficacy, potential weight regain after stopping the medication, and side to Shivane, clinical trails have shown weight regain of 5-7% once the drug is stopped. 'That is where patients will need counselling in order to adopt a healthier lifestyle including healthy dietary habits and regular exercise,' he Kumar Sinha, consultant physician at Mumbai-based WeCare Wellness, said, 'The molecule is good. Global studies suggest there are patients who have benefitted from it, but there are also those who have dropped out due to side effects that are mostly gastrointestinal in nature.' Commonly reported side effects include nausea, vomiting, diarrhoea, constipation and abdominal pain. Sinha said it will take 3-4 months to tell how the drug is working on Indian patients. 'One also has to look at the affordability issue,' he added. In India, Mounjaro is priced at Rs 3,500 for a 2.5 mg vial and Rs 4,375 for a 5 mg vial, which translates to Rs 14,000-17,500 per month, depending on the weekly dose. This means a six month treatment could cost about Rs 1 to a recent study published in leading medical journal Lancet, 70% of India's urban population is classified as obese, or overweight.'Obesity is like a pandemic in India and diabetes is very common and it is one of the useful drugs,' Anurag Lila, visiting consultant endocrinologist at Dr LH Hiranandani Hospital in Mumbai, told ET in a recent interaction.
&w=3840&q=100)
First Post
11 hours ago
- First Post
Lammy meets PM Modi, pushes UK-India counter-terrorism cooperation and trade deal
British Foreign Minister David Lammy is the highest-profile Western official to have visited both New Delhi and Islamabad since the South Asian neighbours agreed to a ceasefire last month after their worst fighting in nearly three decades. read more Britain and India held talks on strengthening their counter-terrorism cooperation in the wake of recent cross-border clashes between India and Pakistan, UK Foreign Minister David Lammy told Reuters on Saturday following a meeting with Indian Prime Minister Narendra Modi. Lammy's visit makes him the most senior Western official to travel to both New Delhi and Islamabad since the South Asian rivals agreed to a ceasefire on May 10, ending their most intense period of conflict in nearly 30 years. STORY CONTINUES BELOW THIS AD Thank you Prime Minister @narendramodi for your warm welcome to India. Building on the free trade agreement between our great countries, we will continue working together to deepen our partnership, celebrate our unique living bridge, and deliver growth and security. — David Lammy (@DavidLammy) June 7, 2025 Indian Prime Minister Narendra Modi stressed the need for decisive international action against terrorism and those supporting it in a meeting with Lammy. The Prime Minister's Office said Lammy strongly condemned the Pahalgam terror attack. PM Modi expressed satisfaction at the successful conclusion of the India-UK Free Trade Agreement and Double Contribution Convention and appreciated the constructive engagement by both sides that led to this milestone. Pleased to meet UK Foreign Secretary Mr. David Lammy. Appreciate his substantive contribution to the remarkable progress in our Comprehensive Strategic Partnership, further strengthened by the recently concluded FTA. Value UK's support for India's fight against cross-border… — Narendra Modi (@narendramodi) June 7, 2025 STORY CONTINUES BELOW THIS AD The PMO statement said Modi welcomed the growing momentum in bilateral ties and expressed satisfaction at the deepening of the India-UK Comprehensive Strategic Partnership. He welcomed the continued collaboration under the Technology Security Initiative and noted its potential to shape trusted and secure innovation ecosystems. Tensions had surged in April after 26 people were killed in India's Kashmir, an incident India blamed on Pakistan-backed militants, which Islamabad denied. In response, India launched strikes on what it described as terrorist infrastructure inside Pakistan, prompting retaliatory moves and escalation until both countries agreed to halt hostilities. 'We want the situation to be maintained, but of course we recognise fragility, particularly in the backdrop of terrorism, terrorism designed to destabilise India,' Lammy said in an interview at the residence of the British High Commissioner in New Delhi. STORY CONTINUES BELOW THIS AD 'We are keen to continue to work with our Indian partners on counter-terrorism measures.' He said he discussed the next steps with both Modi and Indian Foreign Minister S. Jaishankar, but gave no specifics. Last year, India and Britain discussed combating the financing of terrorism, cooperation between law enforcement and judicial bodies and information sharing. Lammy said he also discussed boosting trade between the world's fifth and sixth largest economies. The countries concluded talks for a free trade deal early last month. 'I know that Prime Minister Keir Starmer is very much looking forward to coming to India very soon to sign the free trade agreement,' Lammy said. 'There is so much that our two nations can continue to do together.' With inputs from agencies
